MAZE

ANALYST NOTE: MAZE THERAPEUTICS, INC. (MAZE) DATE: 2026-06-13 CURRENT PRICE: $25.68

1. Structural Readiness

State: Forming Aggressive/Pre-Breakout Entry: $25.68 (Current Price) Breakout Level: — (To be defined as the high of the current consolidation range once the base is fully formed) Current Price: $25.68 Extension: — (Price is not currently extended above a breakout level; it is in the base formation phase.) ATR Current: 4.9% (High) ATR at Breakout: — (Not yet applicable as breakout has not fired)

2. Thesis Layer

Primary Secular Thesis: Biotech & GLP-1 → Rare & Orphan (Tier Direct) Confidence: Moderate Exposure: Maze Therapeutics is a direct beneficiary of the "Rare & Orphan" theme within the broader Biotech sector. The company's pipeline targets specific genetic and metabolic disorders (APOL1 kidney disease, PKU, CKD) where the total addressable market is defined by specific patient populations rather than broad consumer demand. Additional Tailwinds: The company's focus on "human genetics" to develop precision medicines aligns with the secular shift toward mechanism-of-action-driven therapies in kidney and metabolic diseases. The recent milestone payment from Shionogi ($20.0M) validates the commercial potential of their asset class, reinforcing the thesis that their proprietary platform has tangible value.

3. The Business

Company Overview: Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company harnessing human genetics to develop novel, small molecule precision medicines for kidney and metabolic diseases (Evidence E3, E14). Business Model: The company operates on a clinical-stage model, funding operations through cash reserves, debt facilities, and equity offerings to advance drug candidates through clinical trials. Revenue is currently derived from milestone payments and potential future licensing deals, with no commercial product revenue reported as of this date. Key Assets & Pipeline:

Financial Position: As of May 12, 2026, the company secured an initial term loan of $40.0 million with commitments for up to $160.0 million additional tranches through February 2031 (Evidence E1). In April 2026, the company completed an underwritten offering raising approximately $144.7 million in net proceeds and received a $20.0 million milestone payment from Shionogi (Evidence E2). Management believes existing cash and marketable securities are sufficient to fund operations for at least one year from the issuance date of the financial statements (Evidence E4).

• MZE829: An oral small molecule inhibitor of apolipoprotein L1 (APOL1). As of March 2026, it showed positive topline results in a Phase 2 trial for AMKD (Evidence E6). Specifically, treatment resulted in a mean reduction in uACR of 35.6% at week 12, with 50% of patients achieving at least a 30% reduction (Evidence E11). The company plans to advance this into a pivotal development program (Evidence E7).
• MZE782: An oral small molecule blocking the solute transporter SLC6A19. The company plans to initiate two Phase 2 proof-of-concept trials in 2026: one for PKU (mid-2026) and one for CKD (second half of 2026) (Evidence E8, E9, E10).
• Trace License: An exclusive license agreement with Trace Neuroscience for a discovery program targeting UNC13A for ALS (Evidence E5).

4. Archetype and Conviction

Archetype: Growth Leader (Clinical-Stage Biotech) Valuation Context: The financial spine indicates forward consensus EPS of -2.75 for FY1 and -3.22 for FY2 (Evidence E16). This confirms the company is in a pre-revenue, high-burn growth phase typical of clinical-stage biotechs. Valuation is driven by the probability of success (PoS) of the pipeline assets and the runway provided by the recent capital raise. Conviction Stack:

• Thesis Strength: Moderate. The "Rare & Orphan" theme is strong, and the specific targets (APOL1, SLC6A19) are scientifically validated.
• Evidence Quality: High. Recent filings (May 2026) provide concrete data on Phase 2 results (MZE829) and clear capital deployment ($144.7M raise + $40M loan).
• Structural Quality: The recent capital raise and positive clinical data provide a strong foundation for a base formation. However, the high ATR (4.9%) indicates the market is still pricing in significant binary risk.
• Setup Readiness: Low to Moderate. The setup is "Forming." The price is holding above the implied support, but the breakout has not fired. The "forming" state is a positive signal but does not constitute a confirmed entry.
• Rerating Potential: High, contingent on the successful initiation of the Phase 2 trials for MZE782 and the advancement of MZE829 to pivotal stages.

5. Invalidations, Strengtheners, and Gaps

Invalidation Triggers:

• Failure to initiate the planned Phase 2 trials for MZE782 in PKU or CKD as scheduled in 2026.
• Deterioration of cash runway such that management guidance of "one year" of funding is no longer credible.

Strengtheners:

• Confirmation of the Phase 2 trial initiation for MZE782 in mid-2026 and second half of 2026.
• Positive data readouts from the ongoing MZE829 pivotal program.
• Additional milestone payments from partners (e.g., Shionogi).

Gaps in Evidence:

• Commercialization Timeline: No specific dates for potential NDA submissions or commercial launch are provided in the evidence.
• Dilution Impact: While the $144.7M raise is noted, the exact impact on fully diluted share count and the resulting per-share cash position is not detailed in the provided snippets.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Positive Phase 2 topline results for MZE829 showing 35.6% uACR reduction; $144.7M equity raise and $40M term loan secured in 2026; clear management plan to initiate two Phase 2 trials for MZE782 in 2026. Key risks: High ATR (4.9%) indicating elevated volatility and potential for whipsaw; clinical-stage nature with no revenue; potential for trial delays or negative data in upcoming MZE782 studies; cash runway dependent on successful execution of planned trials. Sizing hint: Position size should be conservative relative to the "forming" status and high volatility; treat as a satellite holding pending breakout confirmation. Expected path: Management expects to advance MZE829 to pivotal studies and initiate MZE782 trials in PKU and CKD during 2026; price likely to consolidate as the market digests the capital raise and awaits the next data readouts. Expected horizon: 6 to 12 months for the next major catalyst (trial initiation or data readout).